7Baggers
 Spero Therapeutics Focuses on Tebipenem HBr Program  TipRanks Fri, 14 Nov 2025 05:09:43 GMT
 Spero Therapeutics earnings beat by $0.26, revenue fell short of estimates  Investing.com Nigeria Fri, 14 Nov 2025 01:32:43 GMT
 Spero Therapeutics Reports Q3 2025 Financial Results  TipRanks Thu, 13 Nov 2025 22:52:25 GMT
 Spero Therapeutics Q3 net loss narrows  MarketScreener Thu, 13 Nov 2025 21:34:49 GMT
 Spero therapeutics CEO Rajavelu sells $95k in stock By Investing.com  Investing.com Nigeria Thu, 13 Nov 2025 01:52:30 GMT
 published on: 2025-11-12 18:17:39  newser.com Thu, 13 Nov 2025 00:17:39 GMT
 Insights Ahead: Spero Therapeutics's Quarterly Earnings  Benzinga Wed, 12 Nov 2025 16:02:48 GMT
 published on: 2025-11-01 09:23:51  newser.com Sat, 01 Nov 2025 14:23:51 GMT

Spero Therapeutics, Inc
(NASDAQ:SPRO) 

SPRO stock logo

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HB...

Founded: 2013
Full Time Employees: 57
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends